University of Pennsylvania | Pathology and Laboratory Medicine

DNA-based Vaccine Successfully Eradicates Nearly Half of Precancerous Cervical Lesions in Clinical Trial

September 30, 2015

Use of a novel synthetic platform for creating vaccines originally developed in the Weiner Lab.

Appointment of Laurel Glaser, MD, PhD, as Assistant Director of Clinical Microbiology

September 28, 2015

The Department welcomes Dr. Laurel Glaser, who will be appointed Assistant Director of the Clinical Microbiology Laboratory at HUP.

Roth Lab Publishes in Cell Reports

September 10, 2015

Findings report blood cancers develop when immune cell DNA editing enzyme hits off-target spots in the genome.

Long-Term Remissions in First Group of Patients to Receive Personalized Cellular Therapy for CLL

September 03, 2015

Science Translational Medicine report details the mature results from the initial CAR T cell trial at Penn.

Pathology Residency Program in the Top 10 for Quality of Clinical Training

August 31, 2015

The Pathology Residency Program at the University of Pennsylvania was ranked in this year’s Top 10 Residency Programs by reputation for quality of clinical training as determined by the physician network Doximity.

CAP Inspection Concludes

August 21, 2015

Biennial College of American Pathologists (CAP) inspection of the Department of Pathology and Laboratory Medicine operations.

Novel Synthetic DNA Vaccine Induces Immunity against MERS in Animal Species

August 20, 2015

Weiner Lab publishes in Science Translational Medicine.

Weiner Lab Develops New Approach to Create Immunity to Dengue Fever

August 04, 2015

Entirely new approach to vaccines by creating immunity without vaccination through synthetic nucleic acid antibody prophylaxis/immunotherapy.

Faculty Expertise in Publications on Medical Education and WHO Atlas on Tumors

July 30, 2015

Status of Laboratory Medicine Education at US Medical Schools and the WHO atlas on neoplasms of endocrine organs.

T-cell Receptor Therapy Clinical Trial Results for Patients with Multiple Myeloma

July 20, 2015

Dr. Carl June and colleagues report the results of a clinical trial of adoptively transferred engineered T cells in patients with advanced multiple myeloma in Nature Medicine.